Regnault V, Rivat C, Marcillier P, Pfister M, Michaely J P, Didelon J, Schooneman F, Stoltz J F, Siadat M
INSERM U 284-CO 10, Vandoeuvre les Nancy, France.
Int J Artif Organs. 1990 Nov;13(11):760-7.
A therapeutic immunoadsorption system on immobilized and anti-apolipoprotein B as a plasma cholesterol lowering procedure was optimized. Several antibodies were compared and highest adsorption capacity was obtained with goat polyclonal antibodies. Optimum quantities of antibodies to be immobilized on the gel and quantities of apo-B to be applied to columns were determined. The amount of antibodies released from immunoadsorbents can be minimized by treatment with a 0.005% glutaraldehyde solution with an acceptable reduction rate of adsorption capacity. Each phase, adsorption and desorption respectively, were well-defined and synchronized so two columns could be used in parallel in an automated procedure. In these conditions, the immunoadsorption system can efficiently, specifically and safely remove cholesterol and has to be subjected to clinical trials.
作为一种降低血浆胆固醇的方法,对固定化抗载脂蛋白B治疗性免疫吸附系统进行了优化。比较了几种抗体,发现山羊多克隆抗体具有最高的吸附能力。确定了固定在凝胶上的抗体最佳量以及应用于柱中的载脂蛋白B量。用0.005%的戊二醛溶液处理可将免疫吸附剂释放的抗体量降至最低,同时吸附能力的降低率在可接受范围内。吸附和解吸的每个阶段都定义明确且同步,因此两根柱可在自动化程序中并行使用。在这些条件下,该免疫吸附系统能够有效、特异性且安全地去除胆固醇,必须进行临床试验。